Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes.

Blood glucose concentrations are maintained by insulin secreted from beta-cells located in the islets of Langerhans. There are approximately 2000 beta-cells per islet, and approximately one million islets of Langerhans scattered throughout the pancreas. The islet in type 2 diabetes mellitus (T2D) has deficient beta-cell mass due to increased beta-cell apoptosis and islet amyloid derived from islet amyloid polypeptide (IAPP). Accumulating evidence implicates toxic IAPP oligomers in the mediation of beta-cell apoptosis in T2D. Humans, monkeys, and cats express an amyloidogenic toxic form of IAPP and spontaneously develop diabetes characterized by islet amyloid deposits. However, longitudinal studies of islet pathology in humans are impossible, and studies in nonhuman primates and cats are costly and impractical. Rodent IAPP is not amyloidogenic, thus commonly used rodent models of diabetes do not recapitulate islet pathology in humans. To investigate the diabetogenic role of human IAPP (h-IAPP), several mouse models and, more recently, a rat model transgenic for h-IAPP have been developed. Studies in these models have revealed that the toxic effect of h-IAPP on beta-cell apoptosis demonstrates a threshold-dependent effect. Specifically, increasing h-IAPP transgene expression by breeding or induction of insulin resistance leads to increased beta-cell apoptosis and diabetes. These transgenic rodent models for h-IAPP provide an opportunity to elucidate the mechanisms responsible for h-IAPP-induced beta-cell apoptosis further and to test novel approaches to the prevention and treatment of T2D.

[1]  E. Shafrir,et al.  PSAMMOMYS OBESUS OF THE JERUSALEM COLONY: A MODEL FOR NUTRITIONALLY INDUCED, NON-INSULIN-DEPENDENT DIABETES , 1993, Journal of basic and clinical physiology and pharmacology.

[2]  K. Polonsky,et al.  Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. , 1998, Diabetes.

[3]  R. Unger.  Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications , 1995, Diabetes.

[4]  S. Bonner-Weir,et al.  Imaging β-Cell Death With a Near-Infrared Probe , 2005 .

[5]  W. Soeller,et al.  Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. , 2003, Diabetes.

[6]  B. Pakkenberg,et al.  Increased islet volume but unchanged islet number in ob/ob mice. , 2003, Diabetes.

[7]  J. Frisbie.  Diabetes Mellitus and Preventable Spinal Cord Injury , 2005, The journal of spinal cord medicine.

[8]  S. Haffner,et al.  Effects of Diabetes and Level of Glycemia on All-Cause and Cardiovascular Mortality: The San Antonio Heart Study , 1998, Diabetes Care.

[9]  L. Tartaglia,et al.  Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice , 1996, Cell.

[10]  L. Nieman,et al.  Cushing’s Syndrome , 2019, Canadian Family Practice Guidelines.

[11]  R. Rizza,et al.  Effects of Meal Ingestion on Plasma Amylin Concentration in NIDDM and Nondiabetic Humans , 1990, Diabetes.

[12]  Josep Vidal,et al.  Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. , 2003, Diabetes.

[13]  R. Unger,et al.  Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Orci,et al.  Alteration of Islet Cell Populations in Spontaneously Diabetic Mice , 1978, Diabetes.

[15]  M. Carty,et al.  Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. , 2004, Diabetes.

[16]  A. Edvell,et al.  Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå +/?). , 1999, Endocrinology.

[17]  W. Soeller,et al.  Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Rosenbloom,et al.  Emerging epidemic of type 2 diabetes in youth. , 1999, Diabetes care.

[19]  H. Makino,et al.  Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. , 1989, Biochemical and biophysical research communications.

[20]  M. Plebani,et al.  Diabetes mellitus in pancreatic cancer follow-up. , 1994, Anticancer research.

[21]  Bruce A. Yankner,et al.  Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus , 1994, Nature.

[22]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[23]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Unger,et al.  Fatty acid-induced β cell apoptosis: A link between obesity and diabetes , 1998 .

[25]  H. Joller-jemelka,et al.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.

[26]  J. Halter,et al.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1984, The Journal of clinical investigation.

[27]  W. Soeller,et al.  Treatment With Growth Hormone and Dexamethasone in Mice Transgenic for Human Islet Amyloid Polypeptide Causes Islet Amyloidosis and β-Cell Dysfunction , 1996, Diabetes.

[28]  E. Ziv,et al.  Nutritionally Induced Insulin Resistance and Receptor Defect Leading to β‐Cell Failure in Animal Models , 1999, Annals of the New York Academy of Sciences.

[29]  S. Kahn,et al.  Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. , 2005, American journal of physiology. Endocrinology and metabolism.

[30]  Kenneth H. Johnson,et al.  Islet Amyloid Polypeptide in Human Insulinomas: Evidence for Intracellular Amyloidogenesis , 1994, Diabetes.

[31]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[32]  G A Colditz,et al.  Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men , 1994, Diabetes Care.

[33]  M. Carty,et al.  Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. , 1998, Diabetes.

[34]  C. Betsholtz,et al.  Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. , 1989, Experimental cell research.

[35]  E. Cerasi,et al.  Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. , 1999, Diabetes.

[36]  G. Cooper,et al.  The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. , 1990, Trends in biochemical sciences.

[37]  Postmortem Autolysis in the Pancreas: Multivariate Statistical Study. The Influence of Clinicopathological Conditions , 1990, Pancreas.

[38]  B. Portha,et al.  Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat , 1997, Diabetologia.

[39]  K. Kosaka,et al.  Isoproterenol-stimulated C-peptide and insulin secretion in diabetic and nonobese normal subjects: decreased hepatic extraction of endogenous insulin in diabetes. , 1980, The Journal of clinical endocrinology and metabolism.

[40]  E. D. de Koning,et al.  Human Islet Amyloid Polypeptide Accumulates at Similar Sites in Islets of Transgenic Mice and Humans , 1994, Diabetes.

[41]  R. Robertson,et al.  Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. , 2001, Diabetes.

[42]  B. Ahrén,et al.  Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice , 1998, Diabetologia.

[43]  G. Mithieux,et al.  beta-cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony. , 2001, Diabetes.

[44]  M. Phillips,et al.  Leptin receptor missense mutation in the fatty Zucker rat , 1996, Nature Genetics.

[45]  J. Thijssen,et al.  Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model , 1999, Diabetologia.

[46]  R. Simó,et al.  High Prevalence of Hepatitis C Virus Infection in Diabetic Patients , 1996, Diabetes Care.

[47]  S. Bonner-Weir,et al.  Imaging beta-cell death with a near-infrared probe. , 2005, Diabetes.

[48]  M. Pelleymounter,et al.  Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.

[49]  K. Flegal,et al.  Diabetes, Impaired Fasting Glucose, and Elevated HbA1c in U.S. Adolescents: The Third National Health and Nutrition Examination Survey , 2001 .

[50]  M. Cnop,et al.  Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. , 2001, Diabetes.

[51]  K. Flegal,et al.  Diabetes, impaired fasting glucose, and elevated HbA1c in U.S. adolescents: the Third National Health and Nutrition Examination Survey. , 2000, Diabetes care.

[52]  B. Beaufrère,et al.  Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. , 1986, The American journal of physiology.

[53]  B. Portha,et al.  Impaired insulin secretion and excessive hepatic glucose production are both early events in the diabetic GK rat. , 1996, The American journal of physiology.

[54]  J. H. Johnson,et al.  Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Matthews,et al.  The effect of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide on glucose removal in the anaesthetized rat and on insulin secretion from rat pancreatic isletsin vitro , 1990, Bioscience reports.

[56]  D. Harrison,et al.  The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. , 1999, Diabetes.

[57]  L. de Gennes.  [Cushing's syndrome]. , 1950, Bulletin medical.

[58]  T. Tomita,et al.  Pancreatic Islets of Obese Hyperglycemic Mice (ob/ob) , 1992, Pancreas.

[59]  J. Miyazaki,et al.  Expression of human islet amyloid polypeptide/amylin impairs insulin secretion in mouse pancreatic beta cells. , 1997, Metabolism: clinical and experimental.

[60]  J. Miyazaki,et al.  Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. , 1995, European journal of endocrinology.

[61]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[62]  Robert A Rizza,et al.  Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. , 2003, Diabetes.

[63]  E. Cerasi,et al.  Studies on the pathogenesis of diabetes in acromegaly. , 1967, Acta endocrinologica.

[64]  B. Topp,et al.  Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. , 2001, Diabetes.

[65]  P. C. Butler,et al.  Islet Amyloid Polypeptide: A Review of Its Biology and Potential Roles in the Pathogenesis of Diabetes Mellitus , 1993, Veterinary pathology.

[66]  P. Butler,et al.  Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. , 2003, Diabetes.

[67]  C. Howard.  Longitudinal studies on the development of diabetes in individual Macaca nigra , 1986, Diabetologia.

[68]  R. Hanson,et al.  Comparison of Body Size Measurements as Predictors of NIDDM in Pima Indians , 1995, Diabetes Care.

[69]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[70]  M. Matsuda,et al.  Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. , 2005, American journal of physiology. Endocrinology and metabolism.

[71]  D. Eizirik,et al.  Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. , 2001, Diabetes.

[72]  G. Comi,et al.  Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy. , 2003, Diabetes care.